Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP313702.RAaPh0H2n4OW0CcBRvXBN_AIafjUJRjH-aQtUz-E5IpDE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP313702.RAaPh0H2n4OW0CcBRvXBN_AIafjUJRjH-aQtUz-E5IpDE130_assertion type Assertion NP313702.RAaPh0H2n4OW0CcBRvXBN_AIafjUJRjH-aQtUz-E5IpDE130_head.
- NP313702.RAaPh0H2n4OW0CcBRvXBN_AIafjUJRjH-aQtUz-E5IpDE130_assertion description "[Liver transplant recipients with recurrent HCV (elevated serum aminotransferases, positive serum HCV RNA, and biopsy-proven hepatitis without rejection) received interferon-alpha (1.5-3 million units subcutaneously three times a week) and ribavirin (400-1000 mg p.o.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP313702.RAaPh0H2n4OW0CcBRvXBN_AIafjUJRjH-aQtUz-E5IpDE130_provenance.
- NP313702.RAaPh0H2n4OW0CcBRvXBN_AIafjUJRjH-aQtUz-E5IpDE130_assertion evidence source_evidence_literature NP313702.RAaPh0H2n4OW0CcBRvXBN_AIafjUJRjH-aQtUz-E5IpDE130_provenance.
- NP313702.RAaPh0H2n4OW0CcBRvXBN_AIafjUJRjH-aQtUz-E5IpDE130_assertion SIO_000772 11292302 NP313702.RAaPh0H2n4OW0CcBRvXBN_AIafjUJRjH-aQtUz-E5IpDE130_provenance.
- NP313702.RAaPh0H2n4OW0CcBRvXBN_AIafjUJRjH-aQtUz-E5IpDE130_assertion wasDerivedFrom befree-2016 NP313702.RAaPh0H2n4OW0CcBRvXBN_AIafjUJRjH-aQtUz-E5IpDE130_provenance.
- NP313702.RAaPh0H2n4OW0CcBRvXBN_AIafjUJRjH-aQtUz-E5IpDE130_assertion wasGeneratedBy ECO_0000203 NP313702.RAaPh0H2n4OW0CcBRvXBN_AIafjUJRjH-aQtUz-E5IpDE130_provenance.